Anne E de Papp
Overview
Explore the profile of Anne E de Papp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1023
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eastell R, Black D, Lui L, Chines A, Marin F, Khosla S, et al.
J Bone Miner Res
. 2020 Sep;
36(2):236-243.
PMID: 32916023
Few analyses of antiresorptive (AR) treatment trials relate short-term changes in bone turnover markers (BTMs) to subsequent fracture reduction seeking to estimate the proportion of treatment effect explained (PTE) by...
2.
Bouxsein M, Eastell R, Liu L, Wu L, de Papp A, Grauer A, et al.
J Bone Miner Res
. 2019 Aug;
34(10):1977-1978.
PMID: 31433861
No abstract available.
3.
Bouxsein M, Eastell R, Lui L, Wu L, de Papp A, Grauer A, et al.
J Bone Miner Res
. 2019 Jan;
34(4):632-642.
PMID: 30674078
Meta-analyses conducted >15 years ago reported that improvements in bone mineral density (BMD) were associated with reduction in vertebral and nonvertebral fractures in osteoporosis trials. Numerous studies have been conducted...
4.
Bauer D, Black D, Bouxsein M, Lui L, Cauley J, de Papp A, et al.
J Bone Miner Res
. 2018 Jan;
33(4):634-642.
PMID: 29318649
Few pooled analyses of antiresorptive (AR) treatment trials relate short-term changes in bone turnover markers (BTMs) to subsequent fracture reduction. Such information would be useful to assess new ARs or...
5.
Cheung A, Majumdar S, Brixen K, Chapurlat R, Fuerst T, Engelke K, et al.
J Bone Miner Res
. 2014 Mar;
29(8):1786-94.
PMID: 24643905
The cathepsin K inhibitor odanacatib (ODN), currently in phase 3 development for postmenopausal osteoporosis, has a novel mechanism of action that reduces bone resorption while maintaining bone formation. In phase...
6.
Brixen K, Chapurlat R, Cheung A, Keaveny T, Fuerst T, Engelke K, et al.
J Clin Endocrinol Metab
. 2013 Jan;
98(2):571-80.
PMID: 23337728
Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD) in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective...
7.
Boyce B, Rosenberg E, de Papp A, Duong L
Eur J Clin Invest
. 2012 Sep;
42(12):1332-41.
PMID: 22998735
Background: Bone remodelling maintains skeletal integrity by osteoclasts removing foci of damaged bone and osteoblasts replacing them with new bone. Diseases associated with increased bone resorption have increased remodelling often...
8.
Folkesson J, Goldenstein J, Carballido-Gamio J, Kazakia G, Burghardt A, Rodriguez A, et al.
Bone
. 2010 Nov;
48(3):611-21.
PMID: 21059422
Unlabelled: We evaluated longitudinal effects of alendronate on MRI-based trabecular bone structure parameters derived from dual thresholding and fuzzy clustering (BE-FCM) trabecular bone segmentation. Treatment effects were observed in the...
9.
Burghardt A, Kazakia G, Sode M, de Papp A, Link T, Majumdar S
J Bone Miner Res
. 2010 Jun;
25(12):2558-71.
PMID: 20564242
The goal of this study was to characterize longitudinal changes in bone microarchitecture and function in women treated with an established antifracture therapeutic. In this double-blind, placebo-controlled pilot study, 53...
10.
Stovall D, Beard M, Barbier S, Chen E, Rosenberg E, de Papp A
J Womens Health (Larchmt)
. 2010 Feb;
19(3):491-7.
PMID: 20141367
Background: Although the effects of bisphosphonates in bone are known for postmenopausal women, it is not known if younger postmenopausal women have a similar response. Furthermore, it is not known...